Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Market Voices
Companies
Artem Shendetskii
Artem Shendetskii

Gilead Sciences ASCENT-04 regimen gains Category 1 status in updated NCCN guidelines

Gilead Sciences ASCENT-04 regimen gains Category 1 status in updated NCCN guidelines
Gilead ASCENT-04 gains NCCN status

Gilead Sciences announced that its Phase 3 ASCENT-04 trial results have now been incorporated into the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a Category 1 preferred regimen for certain individuals living with metastatic triple-negative breast cancer (TNBC).

This update marks a significant recognition for Gilead Sciences, positioning its regimen as a new standard of care for a patient group with limited treatment options. The company stated that the NCCN's designation is based on robust clinical evidence from the ASCENT-04 study, highlighting its clinical impact for metastatic TNBC patients.

Gilead Sciences’ growing presence in oncological and infectious disease treatments underscores the company's broader strategy to address pressing global health challenges. This recent recognition by the NCCN follows the company's innovative approaches in other therapeutic areas, including its work amplifying HIV prevention through music and community engagement at SXSW, as detailed in Gilead Sciences asserts.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

SK Hynix debuts on Nasdaq: Largest U.S. offering by foreign company
  • By Mikhail Vnuchkov
  • 11 hours ago
SK Hynix debuts on Nasdaq: Largest U.S. offering by foreign company
Editors' Picks
SpaceX falls out of orbit: Does anyone still want Musk’s stock?
  • By Oleg Tkachenko
  • Yesterday
SpaceX falls out of orbit: Does anyone still want Musk’s stock?
Editors' Picks
The crypto IPO problem: How high-profile listings became investor traps
  • By Eugene Komchuk
  • 08.07.2026
The crypto IPO problem: How high-profile listings became investor traps
Editors' Picks
All Editors' Top Picks

Latest Gilead Sciences News

Why is Gilead Sciences stock down today? Price tests multi-week lows with reversal risk
  • By Ashutosh Sureka
  • 3 hours ago
Why is Gilead Sciences stock down today? Price tests multi-week lows with reversal risk
Financial News
#Forecast #Gilead Sciences
FDA approval for mTNBC therapy cannot lift Gilead Sciences stock as bearish trend persists
  • By Jose Antonio Gastelum
  • 26.06.2026
FDA approval for mTNBC therapy cannot lift Gilead Sciences stock as bearish trend persists
Companies
#Gilead Sciences
Gilead Sciences edges higher to $125.14 as FDA approves new metastatic breast cancer therapy, Gilead Sciences
  • By Hanna Syniavska
  • 25.06.2026
Gilead Sciences edges higher to $125.14 as FDA approves new metastatic breast cancer therapy, Gilead Sciences
Companies
#Gilead Sciences
All Gilead Sciences News
  • Mikhail Vnuchkov
  • 11 hours ago
SK Hynix debuts on Nasdaq: Largest U.S. offering by foreign company
  • Oleg Tkachenko
  • Yesterday
SpaceX falls out of orbit: Does anyone still want Musk’s stock?
  • Eugene Komchuk
  • 08.07.2026
The crypto IPO problem: How high-profile listings became investor traps
  • Anastasiia Chabaniuk
  • 07.07.2026
U.S. Bitcoin reserve: Trump’s unrealized crypto promise
  • Mikhail Vnuchkov
  • 06.07.2026
Aiming for leadership: Payment giants prepare a new stablecoin
  • Elena Nikulina
  • 7 min ago
Euro Pacific Bank was closed illegally in alleged J5 publicity stunt, Peter Schiff states
  • Anastasiia Chabaniuk
  • 7 min ago
Matt Huang: Trade[XYZ] perps show effective price discovery for SK Hynix
  • Hanna Syniavska
  • 32 min ago
Roy Bhasin: New agent wallet targets AI-driven financial actions
  • Yaroslav Dmytrenko
  • 41 min ago
SPVs distribute $100 million allocations among elites, Patrick OShaughnessy notes
  • Olga Shendetskaya
  • 42 min ago
Fed policy rules currently prescribe higher rates, Greg Ip notes
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Eugene Komchuk
  • 6 hours ago
Circle wins approval to establish U.S. national trust bank
Circle wins approval to establish U.S. national trust bank
  • Ivan Andriyenko
  • 7 hours ago
Oil market keeps risk premium as Hormuz traffic stalls
Oil market keeps risk premium as Hormuz traffic stalls
  • Igor Krasulya
  • 9 hours ago
UAE oil output hits record high as Abu Dhabi pushes beyond OPEC limits
UAE oil output hits record high as Abu Dhabi pushes beyond OPEC limits
  • Eugene Komchuk
  • 10 hours ago
Crypto market posts third consecutive quarterly loss
Crypto market posts third consecutive quarterly loss
  • Andrey Mastykin
  • 10 hours ago
Nasdaq futures slip before SK Hynix U.S. debut
Nasdaq futures slip before SK Hynix U.S. debut
Live News
  • Anton Kharitonov
  • Now
Microsoft stabilizes as AI strategy remains in focus
  • Anton Kharitonov
  • Now
Apple extends rally as AI strategy strengthens investor confidence
  • Anton Kharitonov
  • Now
Google rebounds as AI momentum supports investor confidence
  • Mykhailo Ihnatenko
  • Now
Intel stock faces rising volatility ahead of earnings season
  • Anton Kharitonov
  • Now
Bitcoin climbs toward resistance as ETF demand improves
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR